Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
deals
3
×
life sciences
national blog main
national top stories
new york blog main
beta-thalassemia
biotech
boston
dna
fda
new york top stories
san francisco blog main
achromatopsia
azacitidine
bill cassidy
bluebird bio
cancer
cancer immunotherapy
center for medicare and medicaid services
clinical trials
companion diagnostic
dacogen
daniel o'day
decitabine
epigenetics
epizyme
farydak
flagship pioneering
foundation medicine
foundationone cdx
foundationone heme
fulcrum therapeutics
gene therapy
genentech
harvard pilgrim health care
hemophilia
insulated genomic domains
johnson & johnson
What
morning
3
×
acquire
age
agreed
aims
approach
based
big
bigger
biggest
billion
biotech
broad
called
come
confidence
deal
debuts
developing
didn’t
drugs
emerging
epigenetic
epigenetics
field
flagship’s
foundation
gain
gave
gene
genentech
j
johnson
medicine
medicines
meiragtx
momentum
new
omega
panels
Language
unset
Current search:
morning
×
deals
×
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
